

iRHYTHM®

Investor Presentation

March 2021



Safe Harbor

Certain data in this presentation was obtained from various external sources, and neither “iRhythm” or the “Company” nor its affiliates or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy of that data or undertakes to update such data after the date of this presentation. Such data involves risks and uncertainties and is subject to change based on various factors.

The trademarks included herein are the property of the owners and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company.

This presentation and the accompanying oral presentation include forward-looking statements. All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, clinical results, strategy and plans, market size and opportunity, competitive position, industry environment, potential growth opportunities, business model, and our expectations for future operations, are forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors” in our most recent 10-K and 10-Q filed with the SEC. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.

This presentation regarding the Company shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Sales and offers to sell iRhythm securities will only be made in accordance with the Securities Act of 1933, as amended, and applicable SEC regulations, including prospectus requirements.

iRhythm is Redefining the Way Cardiac Arrhythmias are Diagnosed


Single-Use Wearable Sensors



AI-Based Data Analytics



Clinically Actionable Digital Report

Zio ^{XT}		Zio XT Final Report for Report, Patient #16		iRhythm Technologies Tel: (888) 693-2401 www.zioreports.com	
Date of Birth 12/12/67 (51 yrs)	Patient ID	Gender Female	Primary Indication (R94.31) Abnormal electrocardiogram	Enrollment Period 13 days 19 hours 03/22/19, 05:24am to 04/05/19, 12:40am	Analysis Time 13 days 19 hours (after artifact removed)
Prescribing Clinician Dr. E. Physician	Managing Location San Francisco				
Ventricular Tachycardia (4 beats or more)			Episodes 5	Heart Rate	
▼ Fastest VT (HR Range 135-150 bpm, Avg 142 bpm)			HR Range 116-150 bpm	Overall	Max 154 bpm 09:49am, 03/25
			Avg 132 bpm	Min 50 bpm 11:59pm, 03/22	Avg 78 bpm
				Sinus	Max 96 bpm 11:14am, 03/24
				Min 50 bpm 11:59pm, 03/22	Avg 66 bpm

Cardiac Arrhythmia Burden is Immense in the United States

Highly Prevalent

11 million

Have arrhythmias,
incidence increases with
age and risk factors

40%

Lifetime risk of AF for
individuals over age of 55

Utilization of Services

750,000

Hospitalizations/year due
to AF

130,000

Deaths/year due to AF

Financial Burden

5x


Increased risk of stroke
due to AF

\$34 billion

Annual cost of stroke

\$1.8B Existing U.S. Market Opportunity ... with TAM Expansion

5+ million tests per year



Highly Differentiated and Scalable Digital Platform

INNOVATION STACK

Clinical Evidence & In-Network Contracts

>40 peer reviewed clinical publications
95% of U.S. patients (i.e. 300M) contracted and in-network



Patented Biosensor Technologies

Single use, wireless, long-term, continuous data capture with high patient compliance




Information System and Workflow Tools

Integration with EHR and seamless bi-directional exchange of clinical & financial information



Proprietary Data Analytics & Reporting

FDA cleared and peer-reviewed AI algorithms



Patient Data Base

Cloud-based patient repository of 3M+ patient records and 750M+ hours of expertly curated ECG data



Zio^{XT}

Zio^{AT}

...and Beyond


Clinically Proven: Over 40 Peer-Reviewed Publications

Proven AI Algorithms



- iRhythm’s deep neural network (DNN) exceeded Board-certified cardiologist ECG sensitivity for all 12 rhythm classes
- Improves the accuracy and scalability of ECG analysis, reducing the rate of misinterpretations to improve patient management


New “Gold Standard”



- Zio^{XT} as accurate as an implanted pacemaker in detecting AF burden and outperforms other external cardiac monitors

Monitor Type	% Failure to Detect Clinically Relevant AF
Zio ^{XT}	0.0%
CAM	9.5%
Nuubo Vest	23.8%
Event Monitor	38.1%

Operationally Complete: Proprietary New Digital Information System



- ✓ Streamlines clinical workflows
- ✓ Desktop and mobile platform
- ✓ Easier online report interpretation
- ✓ Mobile access to reports on-the-go
- ✓ Device and patient tracking from registration to report delivery
- ✓ Ability to contact patients directly from mobile app with one tap

Faster & more intuitive experience for physicians and clinical staff

International Expansion Led by Positive Recent Developments in the U.K.



NICE National Institute for
Health and Care Excellence


Winner of Artificial Intelligence in Health and Care Award (September 2020)

- Funding to bring Zio to selected NHS sites over 3-year program and measuring clinical, pathway and economic outcomes
- Competitive process run by the Accelerated Access Collaborative with over 530 applicants
- NHS is focused on implementing AI technologies that have the potential to improve health and care outcomes and benefit patients

Zio XT received positive recommendation from NICE (December 2020)

- Recommended as an option for people with suspected cardiac arrhythmias who would benefit from ECG monitoring for longer than 24 hours
- Likely to be cost neutral or cost saving compared with 24-hour Holter monitoring

Silent AF Market Opportunity



- **10M+ individuals** with high risk of asymptomatic AF
- AF is independent risk factor for stroke, heart failure and CV mortality
- AF is frequently not diagnosed until the time of a serious clinical event such as stroke (20-50%) or heart failure (21%)
- 80% of AF related strokes can be prevented through earlier detection and treatment



Positive 3-year Clinical Outcomes Presented at AHA

Results

Endpoint	Results		
	Active Monitoring	Matched Control	p-value
AF Detection Rate	11.4%	7.7%	<0.01
Primary clinical endpoint: Cardiac Event Rate	4.4	5.5	<0.01
Primary safety endpoint: Hospitalizations due to Bleeding	0.32	0.71	0.01

Cardiac Event = Combined Death, Stroke, Myocardial Infarction or Systemic Embolism
Cardiac Event and Hospitalization Rates in Per 100-person years

Conclusions

Active screening for AF, as part of a prospective, pragmatic, direct-to-participant, nationwide study, was associated with **significant improvement in clinical outcomes and safety at 3 years** relative to routine care.

Sponsor:



Collaborators:



Silent AF Market Development: Clinical Evidence Continues to Build

Ongoing AF Screening Trials



SCREEN-AF



StrokeStop2

Clinical Guidelines



2020: Opportunistic screening for AF is recommended in patients ≥ 65 years old, hypertensive patients, and in patients with obstructive sleep apnea. Systematic ECG screening should be considered to detect AF in patients aged ≥ 75 years, or those at high risk of stroke.




2018: Current evidence is insufficient to assess the balance of benefits and harms of screening for atrial fibrillation with electrocardiography (ECG). Updated review ongoing.

Strong Financial Track Record


Sustained High Revenue Growth

Y/o/Y Revenue Growth

+54% +49% +46% +24%




Strong Gross Margins



Improving Operating Leverage

Opex as % of Sales



Well Capitalized

as of 12/31/2020:

- **\$335 million** in cash and cash equivalents + short-term investments
- **\$33 million** in debt

Investment Highlights

- ✓ iRhythm is redefining the way cardiac arrhythmias are diagnosed
- ✓ Our single scalable technology platform is highly differentiated
- ✓ Zio service is proven to create clinical, operational and financial value for our customers
- ✓ Demonstrated TAM expansion with further growth strategies ongoing
- ✓ Strong track record of revenue growth and margin expansion

iRHYTHM[®]

Sources

Slide	Sources
Cardiac Arrhythmia Burden is Immense in the United States	Morillo, C., et al. Atrial fibrillation: the current epidemic. <i>Journal of Geriatric Cardiology</i> , 2017; <i>Circulation</i> , 2018;137:1027-38; Rienstra, M., et al. Symptoms and functional status of patients with atrial fibrillation. <i>Circulation</i> , 2012; Atrial Fibrillation Fact Sheet. CDC, published August 22, 2017. Accessed October 7, 2019. https://www.cdc.gov/dhbsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm ; Wexler, R., et al. Palpitations: Evaluation in the Primary Care Setting. <i>Am Fam Physician</i> , 2017; Probst, M., et al. Analysis of Emergency Department Visits for Palpitations (From the National Hospital Ambulatory Medical Care Survey). <i>Am J Cardiol</i> , 2014; Stroke Facts. CDC, published September 6, 2017. Accessed October 7, 2019. https://www.cdc.gov/stroke/facts.htm .
\$1.8B Existing U.S. Market Opportunity ... with TAM Expansion	Ambulatory Electrocardiography Monitoring Devices, <i>Medtech 360</i> , December 2018
Clinically Proven: Over 30 Peer-Reviewed Publications	Hannun, A.Y., et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. <i>Nature Medicine</i> , 2019. Eysenck, W., et al. A randomized trial evaluating the accuracy of AF detection by four external ambulatory ECG monitors compared to permanent pacemaker AF detection. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019.
mSToPS Positive 3-year Clinical Outcomes Presented at AHA	Steinhubl S.R. et al, 3-year Clinical Outcomes in a Nationwide Pragmatic Clinical Trial Of Atrial Fibrillation Screening - mHealth Screening To Prevent Strokes (mSToPS), <i>presented at the American Heart Association Scientific Sessions</i> , November 2020.
Silent AF Market Opportunity	AHA Heart Disease and Stroke Statistics; Nationwide Inpatient Sample; U.S. Census Bureau, Chiang, C. et al Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice. <i>Circ Arrhythm Electrophysiol</i> , 2012. Turakhia, M.P. et al. Estimated prevalence of undiagnosed atrial fibrillation in the United States. <i>PLoS ONE</i> , 2018; Lin, H. et al. Newly Diagnosed Atrial Fibrillation and Acute Stroke: The Framingham Study. <i>Stroke</i> , 1995., National Stroke Association 2019; <i>BMJ</i> , 2016;354:i4482; <i>PLoS ONE</i> , 2016;11:e0168010; <i>Am Heart J</i> , 2018;199:137-43; <i>Circulation</i> , 2003;107:2920-5.
Silent AF Market Development: Clinical Evidence Continues to Build	https://www.escardio.org/static-file/Escardio/Guidelines/Publications/AFIB/ACNAP_Memo%20Card-AFIB-Final.pdf https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/atrial-fibrillation-screening-with-electrocardiography